Promising growth and investment in the cell therapy industry during the first quarter of 2012

David A Brindley; Natasha L Davie; William A Sahlman; Gregory A Bonfiglio; Emily J Culme-Seymour; Brock C Reeve; Chris Mason

doi:10.1016/j.stem.2012.04.018

Promising growth and investment in the cell therapy industry during the first quarter of 2012

Cell Stem Cell. 2012 May 4;10(5):492-6. doi: 10.1016/j.stem.2012.04.018.

Authors

David A Brindley¹, Natasha L Davie, William A Sahlman, Gregory A Bonfiglio, Emily J Culme-Seymour, Brock C Reeve, Chris Mason

Affiliation

¹ The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK.

PMID: 22560072
DOI: 10.1016/j.stem.2012.04.018

Abstract

In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Transplantation / economics*
Cell Transplantation / trends*
Health Care Sector*
Humans
Investments
United States